Comparative Pharmacology
Head-to-head clinical analysis: DELTALIN versus HECTOROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELTALIN versus HECTOROL.
DELTALIN vs HECTOROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vitamin D analog; binds to vitamin D receptors, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and enhancing bone mineralization.
Synthetic vitamin D analog that binds to vitamin D receptors (VDR), increasing intestinal absorption of calcium and phosphate, and promoting bone mineralization. Also suppresses parathyroid hormone (PTH) production.
0.5 mg orally once daily, titrated to a maximum of 1 mg daily based on response and tolerability.
0.5 to 1.5 mcg intravenously three times weekly during hemodialysis; adjust to maintain serum intact PTH within target range (1.5 to 3 times upper limit of normal). Initial dose: 0.5 mcg three times weekly; may increase by 0.25 to 0.5 mcg at 2- to 4-week intervals.
None Documented
None Documented
Terminal elimination half-life ranges from 24 to 36 hours in adults with normal renal function; may be prolonged (up to 72 hours) in renal impairment.
Terminal elimination half-life is approximately 5.0 hours in healthy adults; prolonged in patients with hepatic impairment.
Renal excretion of unchanged drug accounts for approximately 60-70% of the administered dose; biliary/fecal elimination accounts for 30-40%, primarily as metabolites.
Primarily hepatic metabolism followed by biliary excretion; renal excretion accounts for <2% of unchanged drug.
Category C
Category C
Vitamin D Analog
Vitamin D Analog